Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry

• Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy Vol. 34; no. 1; pp. 89 - 98
• Main Authors: Kim, Hyoun-Ah, Lee, Eunyoung, Lee, Sun-Kyung, Park, Yong-Beom, Lee, Young Nam, Kang, Hee Jung, Shin, Kichul
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2020; Springer Nature B.V
• Subjects: Antibodies; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents; Arthritis, Rheumatoid - drug therapy; Biological products; Biomedical and Life Sciences; Biomedicine; Biosimilar Pharmaceuticals - therapeutic use; Blood Sedimentation - drug effects; C-reactive protein; Cancer Research; Clinical medicine; Data collection; Drug Substitution - methods; Erythrocyte sedimentation rate; Female; Humans; Infliximab; Infliximab - therapeutic use; Joint diseases; Male; Middle Aged; Molecular Medicine; Monoclonal antibodies; Original; Original Research Article; Patients; Pharmacotherapy; Registries; Republic of Korea; Retention; Rheumatoid arthritis; Rheumatology; Rheumatology - methods; Safety; Severity of Illness Index; Studies; Treatment Outcome; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Republic of Korea

Objective The aim was to evaluate long-term drug retention, discontinuation, efficacy and safety of CT-P13 and reference infliximab in patients with rheumatoid arthritis (RA) enrolled in the Korean College of Rheumatology Biologics (KOBIO) registry. Methods Patients included adults with RA who recei...